USANA Health Sciences (NYSE:USNA) Issues FY 2022 Earnings Guidance

USANA Health Sciences (NYSE:USNAGet Rating) updated its FY 2022 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $5.000-$5.700 for the period, compared to the Thomson Reuters consensus estimate of $5.460. The company issued revenue guidance of $1.10 billion-$1.20 billion, compared to the consensus revenue estimate of $1.14 billion.

A number of research analysts recently issued reports on USNA shares. Zacks Investment Research raised USANA Health Sciences from a strong sell rating to a hold rating in a report on Wednesday, April 13th. TheStreet downgraded USANA Health Sciences from a b rating to a c+ rating in a research report on Wednesday, February 9th. StockNews.com started coverage on USANA Health Sciences in a report on Thursday, March 31st. They issued a strong-buy rating on the stock. Finally, DA Davidson initiated coverage on USANA Health Sciences in a report on Wednesday, April 13th. They set a neutral rating and a $86.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of Buy and a consensus target price of $108.33.

NYSE:USNA traded down $2.32 during mid-day trading on Tuesday, hitting $75.52. The company had a trading volume of 91,802 shares, compared to its average volume of 69,959. USANA Health Sciences has a fifty-two week low of $75.52 and a fifty-two week high of $107.85. The firm has a market cap of $1.45 billion, a P/E ratio of 13.39 and a beta of 0.87. The business’s fifty day moving average is $82.70 and its two-hundred day moving average is $93.22.

USANA Health Sciences (NYSE:USNAGet Rating) last released its quarterly earnings data on Tuesday, February 8th. The company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.30 by ($0.27). USANA Health Sciences had a return on equity of 28.84% and a net margin of 9.82%. The firm had revenue of $267.30 million for the quarter, compared to the consensus estimate of $273.00 million. During the same period in the previous year, the business earned $1.87 EPS. As a group, research analysts anticipate that USANA Health Sciences will post 5.51 earnings per share for the current year.

In other USANA Health Sciences news, COO Walter Noot sold 1,885 shares of the stock in a transaction dated Wednesday, February 16th. The stock was sold at an average price of $90.04, for a total transaction of $169,725.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joshua Foukas sold 3,303 shares of the stock in a transaction dated Wednesday, March 2nd. The stock was sold at an average price of $89.93, for a total value of $297,038.79. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,653 shares of company stock valued at $600,825. 0.36% of the stock is owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. Vident Investment Advisory LLC boosted its stake in shares of USANA Health Sciences by 3.0% during the 4th quarter. Vident Investment Advisory LLC now owns 7,690 shares of the company’s stock worth $779,000 after buying an additional 225 shares during the last quarter. Legal & General Group Plc lifted its stake in USANA Health Sciences by 1.4% in the 4th quarter. Legal & General Group Plc now owns 35,666 shares of the company’s stock valued at $3,609,000 after purchasing an additional 489 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in USANA Health Sciences by 1.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 132,542 shares of the company’s stock valued at $12,220,000 after purchasing an additional 1,769 shares during the last quarter. Allianz Asset Management GmbH lifted its stake in USANA Health Sciences by 25.0% in the 4th quarter. Allianz Asset Management GmbH now owns 12,249 shares of the company’s stock valued at $1,239,000 after purchasing an additional 2,452 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its stake in USANA Health Sciences by 8.7% in the 4th quarter. Parametric Portfolio Associates LLC now owns 46,186 shares of the company’s stock valued at $4,674,000 after purchasing an additional 3,707 shares during the last quarter. Institutional investors own 54.82% of the company’s stock.

USANA Health Sciences Company Profile (Get Rating)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.

Featured Stories

Earnings History and Estimates for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.